Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Pre-publication history

An Australian translational Study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT]

Stephen Clarke*, Matt Burge, Cassandra Cordwell, Peter Gibbs, William Reece and Niall Tebbutt

BMC Cancer 2013, 13:120  doi:10.1186/1471-2407-13-120

Pre-publication versions of this article and reviewers' reports

Original Submission - Version 1 15 Aug 2012
Reviewer's Report Stephen Falk 02 Nov 2012
Reviewer's Report Paul Ross 13 Nov 2012
Reviewer's Report raffaele palmirotta 13 Nov 2012
Resubmission - Version 2 Manuscript Author's comment 16 Dec 2012
Editorial acceptance 08 Mar 2013
Published 15 Mar 2013